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doi:10.1016/j.jmii.2011.01.020Background: Candida albicans and Candida glabrata are the major causes of vulvovaginal
candidiasis (VVC) in Indian women with diabetes mellitus. Little information is available
regarding the genotyping of Candida species isolated from Indian diabetic women with VVC.
Methods: In this study, a total of 57 Candida species, comprising Candida albicans and Candida
glabrata, isolated from Indian women with VVC, were genotyped and tested for fluconazole
susceptibility. Arbitrarily primed polymerase chain reaction (AP-PCR) was used to genotype
C glabrata isolates, whereas Southern blot hybridization using a Candida albicans repetitive
element-2 (CARE-2) probe was used to genotype C albicans.
Results: Genotyping showed that all the C albicans isolates were genetically heterogenous.
The pattern of DNA bands obtained after AP-PCR for C glabrata strains were predominantly
conformed to genotype A. In vitro fluconazole-susceptibility testing of the isolates using the
Clinical and Laboratory Standards Institute M27A2 protocol showed that more than 93% of
the Candida isolates were susceptible.
Conclusions: Ninety-five percent of the C albicans isolates analyzed were different and genet-
ically unrelated. The analysis of the AP-PCR DNA banding pattern of C glabrata isolates showed
that it resembled genotype “A”. The Candida isolates were found to be susceptible to fluco-
nazole, with minimum inhibitory concentrations ranging from 0.5 mg/mL to 8 mg/mL. This
correlates with the use of fluconazole as a first-choice antifungal for treating VVC in India.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Dermatology, School of Medicine, University Hospitals Case Medical Center, Case Western Reserve
ad, Cleveland, Ohio 44106, USA.
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Molecular typing and susceptibility of Candida species 167Introduction DNA extractionPatients with diabetes mellitus (DM) are at risk of vulvova-
ginal candidiasis (VVC).1,2 Candida albicans is still one of the
most common species isolated in women with VVC. Recent
studies have shown that non-albicans species of Candida are
the major cause of such infections in patients with DM
compared with those in nondiabetic individuals.1,3 Candida
glabrata is the most common non-albicans Candida species
isolated from women with DM and VVC.1,3 We hypothesized
that the differences in the prevalences of C glabrata
infection in patients with or without DM could be the result
of the differences in the molecular genotypes of species
from these groups of patients with or without DM.
Recently, Becker et al.4,5 characterized C glabrata
strains isolated from nondiabetic women by arbitrarily
primed polymerase chain reaction (AP-PCR) with multiple
sets of primers. Three distinct molecular subtypes were
identified by primer AP50-1.4,5 Candida albicansespecific
DNA probe “CARE-2” has also been used recently for gen-
otyping Candida isolates.6e8 The present pilot study was,
therefore, conducted to assess the differences in the
genotypes between C albicans and C glabrata isolates
recovered from diabetic women with VVC attending
a tertiary care hospital in New Delhi, India. The minimum
inhibitory concentrations (MICs) of fluconazole against all
the isolates were also determined.Methods
Test isolates
A total of 57 isolates of Candida species were evaluated. Out
of these, 22 and 7 were C glabrata obtained from diabetic
and nondiabetic women, respectively. Also included were 21
and 7 C albicans isolated from diabetic and nondiabetic
women, respectively. These isolates were identified and
characterized previously by Goswami et al.1,3 The isolates
were preserved in 15% glycerol and stored at 80C.
All of the isolates included in this study were collected
randomly from diabetic and nondiabetic women with VVC
symptoms. All of them were attending the clinic as outpa-
tients of the All India Institute of Medical Sciences, New
Delhi, India. Samples were collected with two sterile cotton
swabs to collect discharge from high vagina.1,3 One swabwas
used to detect the presence of any yeast by Gram staining,
and the otherwas used to test growth on Sabouraud dextrose
agar slants containing 2 mg of gentamicin per mL and 0.5%
cycloheximide. In the case of positive growth, yeast identi-
fication was done by conventional methods. The method
used was the germ tube production test, which was done by
the inoculation of a single colony into 0.5 mL of horse serum,
followed by incubation at 37C for 2 hours. Morphology
testing for the presence of chlamydospores, pseudohyphae,
true mycelium, and blastospore arrangement was done on
corn meal agar. An enzymatic triphenyl tetrazolium chloride
reduction test was performed, in which each Candida spe-
cies grows with a distinct texture and color. For further
characterization, each isolate was subjected to carbohy-
drate assimilation and fermentation tests.1,3,6Chromosomal DNA was isolated from each sample using
conventional technique after lysis of the cells by Zymolyase
(Seikagaku Biobusiness Corporation, Japan) treatment as
described previously.6
Genotyping of Candida glabrata
Genotyping of C glabratawas done by AP-PCR. AP50-1 primer
(5’-GATTCAGACC-3’) was used to amplify chromosomal DNA
in 50 mL of PCR reaction mixture as described previously by
Becker et al.4,5 Briefly, the PCR mixture contained Deoxy-
nucleotides Triphospahte (dNTPs) 100 mM (each) dATP, dCTP,
dGTP, and dTTP; enzyme buffer; 50 pmol primer; and 2.5 U
Taq-polymerase. The amplification was performed in an
automated thermocycler (iCycler, Bio-Rad, Philadelphia, PA,
USA). The thermal cycling conditions were 30 cycles of
denaturation at 94C for 1 minute (2 minutes for the first
cycle), annealing at35C,andextensionat72C for 2minutes.
Amplified products (50 mL) were resolved by 1% agarose gel
electrophoresis at 100 V for 1.5 hours. The gel was stained
with ethidium bromide; exposed to UV light to visualize the
amplified products; and photographed (MultiImage, Alpha
Innotech Corporation, Santa Clara, CA, USA). All experiments
were performed in triplicates. Because of low discriminatory
power of AP-PCR, caution should be practiced in the inter-
pretation of AP-PCR data.
Genotyping of Candida albicans
DNA fingerprinting of the C albicans isolates by Southern
blot hybridization was done as described earlier.6 In brief,
chromosomal DNA (2 mg) from each isolate was digested
with restriction enzyme EcoRI till completion at 37C for
2 hours. The digested DNA samples were then electro-
phoresed on agarose gel (0.8%) in 1 Tris/Borate/EDTA
(TBE) buffer (89 mM Tris-borate and 1 mM EDTA) by
applying a voltage gradient of 2 V/cm for a period of 20
hours; stained with ethidium bromide (0.5 mg/mL);
destained; visualized under UV; and photographed using gel
documentation system (MultiImage). Separated DNA frag-
ments were denatured in situ using an alkali and were then
neutralized with an acid. The denatured DNA fragments
were then transferred to nylon membrane (Sigma-Aldrich,
St. Louis, MO, USA) by capillary action. The transferred DNA
fragments were then UV cross-linked (Stratagene, Santa
Clara, CA, USA) to the membrane and prehybridized in
300 mM phosphate buffer containing 7% sodium dodecyl
sulfate (SDS) and 1 mM EDTA at 65C for 2e4 hours.
Immobilized DNA fragments were hybridized with
C albicansespecific probe CARE-2 labeled with [a-32P]dATP
(Amersham Pharmacia Biotech, Buckinghamshire, UK) at
the same temperature for 16 hours.6 Briefly, CARE-2 probe
was prepared as follows.
Labeling of CARE-2 probe
About 5e10 mg of plasmid DNA (pRFL37) containing the
CARE-2 sequence was digested with restriction enzyme KpnI
and PstI, and the generated DNA fragments were separated
168 A.A. Lattifon 1% agarose gel ran in 1 TBE buffer. The 1.06-kb DNA
fragment containing the CARE-2 sequence was then cut out
of the gel, homogenized, and suspended in 1 Tris-EDTA (TE)
buffer and eluted out of the agarose. The purified DNA
fragment was hybridized to random primers (Takara, Shiga,
Japan) and extended in presence of 200 mM each of dGTP,
dCTP, and dTTP, and 10 mCi [a-32P]dATP (6,000 Ci/mmol), by
Klenow fragment at 30C for 30 minutes; the labeled DNA
fragment was then precipitated with absolute ethanol and
washed several times with 70% ethanol to get rid of unin-
corporated nucleotides. Finally, the precipitated DNA was
dissolved in hybridization buffer and used for hybridization.
After hybridization, the nylon membrane was washed
several times with 2 sodium chloride and sodium citrate,
containing 0.1% SDS; exposed to X-ray film at 80C for
16e24 hours; and developed. All experiments were carried
out in triplicate. The DNA fingerprinting was further
confirmed when analyzed quantitatively using Dendron
software package, version 3.0 (Solltech, Iowa City, IA, USA)
as described by Pujol et al.9
In vitro tests for fluconazole susceptibility
Susceptibility testing of isolates to fluconazole was carried
out as stipulated in the National Committee for Clinical
Laboratory Standard CLSI/NCCLS M27A2 protocol (2002).
Briefly, fluconazole (Ranbaxy, Haryana, India) was dissolved
in sterile distilled water. The drug was serially diluted in
Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-
Ardrich) with L-glutamine but without sodium bicarbonate
and buffered at pH 7.0 with morpholinepropanesulfonic
acid. The final drug dilution ranged from 0.125 ug/mL to
64 ug/mL. The inocula were prepared in 0.9% sterile normal
saline from five to seven single Candida colonies grown on
Sabouraud’s dextrose agar for 16 hours at 37C to attain
a turbidity equivalent to 0.5 MacFarland Standard.
Microdilution plates were set up, and each test plate
had two drug-free-growth controls, one with media alone
(sterility control) and the other with media and test isolate
Candida isolates without fluconazole (growth control).
Quality controlwas performedby testing CLSI-recommended
strains Candida krusie ATCC 6285 and Candida parapsilsosis
ATCC 22019. The plates were incubated at 35C and read
after 48 hours of incubation. Endpoint determinations were
made by visually comparing the growth in the wells con-
taining the drug with the growth in the drug-free wells. The
MIC reported at 80% (MIC80) was the lowest concentration of
fluconazole that caused 80% inhibition of growth.
Results
Figure 1 shows the genotyping pattern observed after AP-PCR
ofC glabrata isolates obtained from22 patientswith VVC and
DM, and seven patients without DM but with VVC. The AP50-1
primer used showed good band pattern with high percentage
of polymorphism. All C glabrata strains tested showed the
specific amplification products to the primer used. One main
cluster profile was observed for all the isolates of C glabrata
(Figs. 1A and 1B) from diabetic and nondiabetic patients.
Three distinct major bands characterized the first cluster
designated as “A.”4,5 The DNA banding patterns obtained inall of them were analyzed and were found to be similar to
genotype “A.”
The DNA fingerprinting patterns of the 21 isolates of
C albicans from the patients with diabetes and eight isolates
fromthenondiabetic individuals are shown inFigs. 2Aand2B.
The CARE-hybridization patterns of these isolates were
found to be relatively complex (Fig. 2). The genotyping
pattern of each of the isolates was specific for individual
Candida isolates and did not relate to one another both in the
diabetic and in the nondiabetic groups. This further
confirmed that all the C albicans isolates were different and
genetically unrelated, except Isolates 1 versus 5 from dia-
betic women and Isolates 5 versus 6 from nondiabetic
women. The DNA genotyping pattern was further confirmed
by Dendron software package, version 3.0 (Fig. 3). Our data
showed unrelatedness of most of the C albicans isolates,
which may indicate different sources of infection.
The comparison of in vitro fluconazole-susceptibility
patterns in diabetic and nondiabetic women revealed that
more than 93% of theCandida isolates obtained fromdiabetic
women were susceptible, with MICs ranging from 0.5 mg/mL
to 8 mg/mL, and the most common MIC among diabetic
women (mode) was 4 mg/mL. Two of the Candida isolates
(C albicans Isolate 21 and C glabrata Isolate 10) tested were
found to be dose-dependently susceptible, with MICs ranging
from 16 mg/mL to 32 mg/mL. However, C glabrata Isolate 7
and two C albicans isolates (Isolates 9 and 15) were found to
be resistant, with MICs greater than or equal to 64 mg/mL. All
the Candida isolates obtained from nondiabetic women were
fluconazole susceptible (0.5e8 mg/mL) andmode of 2 mg/mL.Discussion
There are relatively few studies that highlight the problem
of VVC among Indian diabetic patients; thus, it remains
a poorly investigated area. In recent years, VVC caused by
C glabrata has been increasingly isolated from women with
DM. First, we analyzed the genotyping of C glabrata isolates
to get an insight on the genotypes of C glabrata that cause
VVC in Indian women. There is a wide prevalence of Candida
species in patients with DM.1,10 In a previous study by Gos-
wami et al.,1 it was found that the occurrence of VVC was
significantly (pZ 0.0025) higher in diabetic women (46%)
compared with that in nondiabetic women (23%). In a study
by Nowakowska et al.10 a similar but increased prevalence
was observed among diabetic pregnant women (40.4%)
compared with that in nondiabetic pregnant women (13.6%).
The increased prevalence of Candida species infection
among diabetics has long been postulated to be either
because of host- or pathogen-related factors.11 Most of the
pathogens, including Candida species, have developed an
effective battery of putative virulence factors and particular
strategies that help them to colonize host tissues, cause
disease, and overcome host defenses.12e14 The site of
infection (host factors) has a direct correlation with the
virulence of the Candida species. The vulvovaginal tissues
have unique conditions that may induce the virulence of the
Candida species, which include the pH, the temperature,
the adherence capacity expression of Candida, and the
concentrations of the nutritionalmaterial that are necessary
for the virulence of Candida species.12e14
Figure 1. (A) Agarose gel patterns demonstrating the AP-PCR with AP50-1 primer of the representative Candida glabrata isolates
obtained from diabetic patients with VVC. (B) Agarose gel patterns demonstrating the AP-PCR with AP50-1 primer of the C glabrata
isolates obtained from nondiabetic patients with VVC (total 7 isolates). The numbers on the top of the figure indicate isolate
numbers. The arrows point out the main band patterns. AP-PCRZ arbitrarily primed polymerase chain reaction; MZmolecular
weight marker (1-kb ladder; New England Biolabs, Ipswich, MA,USA); VVCZ vulvovaginal candidiasis.
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C glabrata isolates might belong to the “A” genotype.
Specific and individualized genotype in all the cases indi-
cated endogenous rather than exogenous source of infectionFigure 2. (A) DNA fingerprinting patterns of Candida albicans
VVCdEcoR1-digested genomic DNAdwere hybridized with labeled
represent C glabrata isolates (negative control, no hybridization b
(B) DNA fingerprinting patterns of C albicans isolates obtained f
DNAdwere hybridized with labeled CARE-2 probe. Lanes 8, 9, 10,
hybridization bands with CARE-2 probe); the rest are all C albicans
numbers. MZmolecular weight marker (1-kb ladder; New Eng
VVCZ vulvovaginal candidiasis.(from the environment, contamination while examining the
patients, or while performing mycological tests in the labo-
ratory). Different genotypes of all the isolates and lack of
differences between diabetic and control groups alsoisolates (21 isolates) obtained from diabetic patients with
C albicansespecific CARE-2 probe. Lanes 7, 8, 14, 22, and 23
ands with CARE-2 probe); the rest are all C albicans isolates.
rom nondiabetic patients with VVCdEcoR1-digested genomic
11, and 12 represent C glabrate isolates (negative control, no
isolates. The numbers on the top of the figure indicate isolate
land Biolabs); CZ control C albicans strain (ATCC 10261);
Figure 3. Dendrogram generated from the similarity coeffi-
cient (SABs) compared all possible pairs of the 21 isolates fin-
gerprinted with the CARE-2 probe.
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involved in the pathogenesis of thewidely prevalentCandida
infection among patients with DM. In a study by Lian et al.15
on VVC in nondiabetic women, it was concluded that the AP-
PCR amplification products were similar among isolates from
different individuals. In India, there appears to be a higher
glycosylated hemoglobin (HbA1) level in patients with DM
and VVC as compared with diabetics without VVC
(12.8 2.6% vs. 9.7 1.7%, respectively; pZ 0.001).1 Now-
akowska et al.10 have also highlighted the predominant role
of poor glycemic control in the high prevalence of VVC in
pregnant women with DM. Lack of genetic differences in the
Candida species between diabetic group and control group
indicates that much emphasis should be placed on achieving
better glycemic control in diabetic patients so as to decrease
the rate of Candida prevalence in such infections in them.
The pattern of DNA genotyping was specific for each
C albicans isolate and did not correlatewith each other in the
diabetic and nondiabetic groups. The heterogenous nature of
the DNA fingerprinting was further confirmed when analyzed
quantitatively using Dendron software package, version 3.0,
as described by Pujol et al.9,16 This indicates that most of the
C albicans isolates were different and genetically unrelated
(Fig. 3). This seems to suggest that there were different
sources of Candida infection among the patients sampled.
Although candidiasis is mainly an endogenous infection, it is
not possible to speculate the primary source of infection.
However,we cannot rule out the possibility that a commensal
may suddenly become a pathogen if the existing conditions
permit. This is consistent with our previous study onoropharyngeal candidiasis in human immunodeficiency virus/
AIDS patients.6
In vitro fluconazole-susceptibility testing of all the
isolates showed that more than 93% of the Candida isolates
were susceptible. Factors contributing to fluconazole
resistance are numerous and include the degree of immu-
nosuppression and prior fluconazole exposure of the pati-
ent, the contribution of other chemotherapeutic drugs, and
the intrinsic resistance of Candida species. In the past,
antifungal drug prophylaxis was rarely practiced in India.
However, over the years, the situation is gradually changing
and increasing number of Indian patients are now receiving
fluconazole therapy, which is the most widely used drug for
treating VVC in India.1e3 In a comparison of our in vitro drug
susceptibility data with those of Houang et al.’s17 clinical
study, where they reported that the oral therapy of
administration of a single dose of 150 mg of fluconazole for
nondiabetic women with VVC inhibited the growth of 90% of
Candida species isolates, a clinical correlation between the
in vitro fluconazole-susceptibility profile and clinical
response was found.
This study is probably the first genotyping VVC study of
diabetic women in India in which comprehensive data were
generated; this will help not only in patient management
but also in future clinical research. More studies using
greater number of samples and repeated collection of
isolates from the same patients at different time intervals
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